---
title: "上海君實生物醫藥科技股份有限公司 (01877.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01877.HK.md"
symbol: "01877.HK"
name: "上海君實生物醫藥科技股份有限公司"
industry: "生物技術"
---

# 上海君實生物醫藥科技股份有限公司 (01877.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.junshipharma.com](https://www.junshipharma.com) |

## Company Profile

生物醫藥的研發,並提供相關的技術開發、技術咨詢、技術轉讓、技術服務,從事貨物及技術的進出口業務。藥品批發,藥品委托生產。(詳見藥品上市許可持有人藥品注冊批件)【依法須經批准的項目,經相關部門批准後方可開展經營活動】

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 17 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.50% |  |
| Net Profit YoY | 47.87% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.16 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 21.52B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.68B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -15.33% | E |
| Profit Margin | -38.25% | E |
| Gross Margin | 84.45% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.50% | A |
| Net Profit YoY | 47.87% | B |
| Total Assets YoY | 6.16% | B |
| Net Assets YoY | -1.14% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -261.41% | D |
| OCF YoY | 37.50% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.22 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 46.14% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 上海君實生物醫藥科技股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-15.33%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-38.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "84.45%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "37.50%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "47.87%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.16%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.14%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-261.41%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "37.50%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "46.14%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.56 | 47/70 | - | - | - |
| PB | 3.30 | 19/70 | 4.33 | 3.61 | 2.53 |
| PS (TTM) | 8.26 | 19/70 | 11.88 | 9.16 | 7.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-01T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 60% |
| Overweight | 0 | 0% |
| Hold | 1 | 20% |
| Underweight | 1 | 20% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 21.88 |
| Highest Target | 37.85 |
| Lowest Target | 20.46 |

## References

- [Company Overview](https://longbridge.com/en/quote/01877.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01877.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01877.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
